Pre-treatment T-cell Transcriptional Signatures Predict Immunotherapy Outcomes in Melanoma
Distinct signatures in the adjuvant and metastatic settings suggest differences in T-cell programs associated with patient outcomes, and support further evaluation of pre-treatment circulating T-cell transcriptional profiles as predictors of ICI response and toxicity in melanoma.